SciTech Development's ST-001 nanoFenretinide Advances to Phase 1b for T-Cell Lymphomas

Key Insights

• SciTech Development's ST-001 nanoFenretinide has progressed to the Phase 1b stage, focusing on clinical activity and response rates in T-cell lymphomas.
• The Phase 1b trial is actively enrolling patients at nine medical centers across the United States, building on promising Phase 1a results.
• A separate trial evaluating ST-001 in Small Cell Lung Cancer is scheduled to commence in the second quarter of 2025, expanding its potential application.

SciTech Development, Inc. has announced the advancement of its clinical trial for ST-001 nanoFenretinide to the Phase 1b stage. This phase will focus on a detailed evaluation of clinical activity and response rates in patients with T-cell lymphomas.

The Phase 1b trial is currently underway at nine medical centers throughout the United States. These centers are actively recruiting patients according to specific trial criteria. The advancement to this stage follows promising preliminary results from the accelerated Phase 1a trial.

Expansion to Small Cell Lung Cancer

In addition to the T-cell lymphoma trial, SciTech Development plans to initiate a separate trial in the second quarter of 2025 to investigate the efficacy of ST-001 nanoFenretinide in Small Cell Lung Cancer. This expansion indicates the company's commitment to exploring the therapeutic potential of ST-001 across various cancer types.

About ST-001 nanoFenretinide

ST-001 nanoFenretinide is an innovative cancer therapeutic developed by SciTech Development. The company aims to address unmet medical needs in oncology by creating effective and affordable treatments. SciTech Development is an oncology-focused pharmaceutical company committed to developing innovative cancer therapeutics.